Abstract
We describe novel rifamycins that have improved activity, compared with rifampin, against clinical isolates of staphylococci and streptococci, with MIC90s of 0.008 and 0.0005 μg/ml, respectively. This enhanced antibacterial activity, along with their potential lack of drug–drug interactions, are considerations that suggest the potential of these novel rifamycins in combination therapy to treat serious Gram-positive infections.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Murphy, C., Karginova, E., Sahm, D. et al. In Vitro Activity of Novel Rifamycins against Gram-positive Clinical Isolates. J Antibiot 60, 572–576 (2007). https://doi.org/10.1038/ja.2007.72
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ja.2007.72